Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Approximately 35-40% of patients with classic infantile Pompe disease treated with enzyme replacement therapy (ERT) develop high, sustained antibody titers against the therapeutic enzyme alglucosidase alfa, which abrogates the treatment efficacy. Induction of antigen-specific immune tolerance would greatly enhance ERT for these patients. Here we show that a short-course treatment with non-depleting anti-CD4 monoclonal antibody successfully induced long-term ERT-specific immune tolerance in Pompe disease mice. Our data suggest an effective adjuvant therapy to ERT.

Original publication

DOI

10.1016/j.ymgmr.2014.08.005

Type

Journal article

Journal

Mol Genet Metab Rep

Publication Date

2014

Volume

1

Pages

446 - 450

Keywords

Anti-CD4 antibody, Antigen-specific immune tolerance, CRIM, cross-reacting immunologic material, ERT, enzyme replacement therapy, Enzyme replacement therapy, GAA, acid-α-glucosidase, IPD, infantile Pompe disease, ITI, immune tolerance induction, MTX, methotrexate, Pompe disease